Difficulty: Medium
Average Score: 70%
Practice
The ß-adrenergic blocker which possesses both ß1 selectivity as well as intrinsic sympathomimetic activity is
Correct answer
C
Rationale
The correct answer is C) Acebutolol. Acebutolol is a ß-adrenergic blocker that exhibits both ß1 selectivity and intrinsic sympathomimetic activity.
Acebutolol's ß1 selectivity means it primarily targets the ß1 receptors in the heart, making it effective in treating conditions like hypertension and angina without affecting other ß receptors in the body. This selectivity helps minimize unwanted side effects commonly associated with non-selective ß blockers.
Intrinsic sympathomimetic activity (ISA) refers to the partial agonist activity of a ß blocker, allowing it to stimulate ß receptors to a lesser extent than full agonists. This property can be beneficial in certain patients, as it may help maintain cardiac output and prevent bradycardia.
Now, let's analyze the other options:
A) Alprenolol: Not the correct answer as it is a non-selective ß blocker without intrinsic sympathomimetic activity.
B) Atenolol: Not the correct answer as it is a ß1 selective blocker but lacks intrinsic sympathomimetic activity.
D) Metoprolol: Not the correct answer as it is a ß1 selective blocker without intrinsic sympathomimetic activity.
Understanding the pharmacological properties of different ß blockers is crucial for healthcare professionals when selecting the most appropriate medication for individual patients based on their unique clinical presentations and comorbidities. Mastery of this topic is vital for safe and effective medication management in various cardiovascular conditions.
Acebutolol's ß1 selectivity means it primarily targets the ß1 receptors in the heart, making it effective in treating conditions like hypertension and angina without affecting other ß receptors in the body. This selectivity helps minimize unwanted side effects commonly associated with non-selective ß blockers.
Intrinsic sympathomimetic activity (ISA) refers to the partial agonist activity of a ß blocker, allowing it to stimulate ß receptors to a lesser extent than full agonists. This property can be beneficial in certain patients, as it may help maintain cardiac output and prevent bradycardia.
Now, let's analyze the other options:
A) Alprenolol: Not the correct answer as it is a non-selective ß blocker without intrinsic sympathomimetic activity.
B) Atenolol: Not the correct answer as it is a ß1 selective blocker but lacks intrinsic sympathomimetic activity.
D) Metoprolol: Not the correct answer as it is a ß1 selective blocker without intrinsic sympathomimetic activity.
Understanding the pharmacological properties of different ß blockers is crucial for healthcare professionals when selecting the most appropriate medication for individual patients based on their unique clinical presentations and comorbidities. Mastery of this topic is vital for safe and effective medication management in various cardiovascular conditions.